Rubius’s New Cell Therapy Strategy Runs Out of Time & Money; Workforce Is Cut by 82%

Rubius Therapeutics was unable to secure financing to carry out its pivot to a new manufacturing process for its red blood cell-based cell therapies. The once high-flying biotech is now exploring options that could include a sale of the business or a merger with another company.